HTEC to Support Digital Telco Enabler Telness Tech in Platform Software Development
17.9.2024 18:31:00 CEST | Business Wire | Press release
Telness Tech, a fast-growing international software company founded in Sweden, and HTEC, a global end-to-end digital product development and engineering services company, are pleased to announce their work on Telness Tech’s innovative platform, which will support the company’s ongoing expansion into new markets, like the US.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240917678716/en/
In this partnership, HTEC will support Telness Tech by providing additional engineering expertise for the new platform’s deployment, customization, and user migration from legacy platforms. HTEC will also assist in the development of business-to-consumer (B2C) applications and various network integrations, including building an abstraction layer for easier integrations. (Graphic: Business Wire)
The platform’s proprietary software is a cloud-based, end-to-end solution for mobile virtual network operators (MVNOs) that offers comprehensive operations and business support system (OSS/BSS) capabilities. It streamlines and automates the customer journey, deploying quickly and remotely without the need for traditional telco infrastructure or legacy IT systems. The platform has already helped Telness Tech clients boost customer ratings in Europe.
In the partnership, HTEC will support Telness Tech by providing additional engineering expertise for the new platform’s deployment, customization, and user migration from legacy platforms. HTEC will also assist in the development of business-to-consumer (B2C) applications and various network integrations, including building an abstraction layer for easier integrations.
Commenting on the collaboration, HTEC’s Director of Engineering & Delivery Bojan Šukalo said:
“Recent tech innovations have transformed how we communicate, but many in the telco industry still use traditional infrastructure. With HTEC’s technical expertise and engineering capacity, we’re perfectly positioned to support the industry’s digital transformation and aligned with Telness Tech to steer the industry forward.”
Founder and COO of Telness Tech, Jonas Cedenwing, highlighted the value of HTEC’s support in this expansion:
“With high demand for our software across the globe, partnering with HTEC ensures that our clients’ platform demands and transitions remain smooth and streamlined, enabling us to continue our high expansion rate without compromising quality.”
About Telness Tech
Founded in Sweden with offices in the US, Telness Tech provides everything needed to launch or run a fully automated mobile operator. The company’s end-to-end BSS/OSS solutions streamline customer journeys, provisioning, and porting — necessary functions to run a digital mobile operator. As a result, satisfied clients drastically reduce operational costs.
About HTEC
HTEC Group Inc. is a global premium technology services firm powering the technological evolution of the world’s most impactful organizations—from disruptive startups to the Fortune 500. HTEC combines deep engineering expertise with remarkable creativity, enabling its customers to innovate, design, and develop disruptive technologies and new digital solutions across different industries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240917678716/en/
Contacts
HTEC Media Relations: media@htecgroup.com
HTEC Media Relations: media@htecgroup.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom